Details
Category: Volume 07 Issue 05 May 2019
Hits: 1215

Title: Lipid Profile and Lipid Peroxidation Levels of Chronic Kidney Disease Patients (CKD) in Sokoto

Authors: C.A. Otitolaiye, A.M. Makusidi, A. Onu, N. B Muhammad, H.B. Zainab

 DOI: https://dx.doi.org/10.18535/jmscr/v7i5.57

Abstract

Introduction: Chronic kidney disease (CKD) is a common and serious problem that adversely affects human health, limits longevity and increases costs of health-care systems worldwide. This study investigated lipid profile and lipid peroxidation levels as risk factors for cardiovascular disease among CKD patients.

Method: The study group consisted of 67 patients attending Nephrology Units of Usmanu Danfodiyo University Teaching Hospital (UDUTH) and Specialist Hospital, Sokoto. The total cholesterol, triglycerides, HDL-C, LDL-C and VLDL-C were analyzed using standard procedures. Atherogenic Index (AIX) was calculated from the ratio of LDL-C to HDL-C. The markers of lipid peroxidation analysed were malondialdehyde (MDA) and oxidised-Low density lipoprotein (ox-LDL).

Results: The levels of LDL-C, VLDL-C and LDL-C/HDL-C ratio were significantly higher (p<0.05) while the level of HDL-C was significantly lower (p<0.05) among the CKD patients when compared to the healthy controls. The correlation of HDL with LDL/HDL ratio (Atherogenic index) showed a significant (p = 0.0001) negative correlation coefficient while LDL and LDL/HDL ratio showed a significant positive correlation coefficient. The plasma levels of malondialdehyde and oxidized LDL were significantly (p<0.05) higher in CKD patients than controls. There was a progressive increase in the plasma levels of both MDA and ox-LDL with advancing CKD. The correlation of eGFRwith markers of lipid peroxidation indicated a significant (p<0.0001) negative correlation coefficient.          

Conclusion: This study showed an increase in atherogenic index and lipid peroxidation products (MDA and ox-LDL) but a decreased HDL-cof the CKD patients, thereby increasing the cardiovascular risk of the CKD patients as CKD advances in stages.

Keywords: chronic kidney disease, malondialdehyde, atherogenic index, estimated glomerular filtration rate.

References

  1. Ardhanari S., Alpert M.A. and Aggarwal K. (2014) Cardiovascular disease in CKD: Risk factors, Pathogenesis, and Prevention. Advances in Peritoneal dialysis. Vol 30;40-53
  2. Bowden and Wilson
  3. Chung S., Koh E. S., Shin S. J. and Park C. W. (2012) Malnutrition in patients with chronic kidney disease. Open Journal of Internal Medicine.2: 89-99
  4. Di-Angelantonio E., Chowdhury R., Sarwar N., Aspelund T., Danesh J., and Gudnason V. (2010) Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. British Medical Journal 341:c4986
  5. Dutta D., Calvani R., Bernabei R., Leeuwenburgh C. and Marzetti E. (2012) Contribution of impaired mitochondrial autophagy to cardiac aging: mechanisms and therapeutic opportunities. Circulation Research. 110(8): 1125-38
  6. Ehara H., Yamamoto-Honda R., Kitazato H., Takahashi Y., Kawazu S., and Akanuma Y. (2012) ApoE isoforms, treatment of diabetes and the risk of coronary heart disease. World Journal of Diabetes. 15;3(3):54-9.
  7. Flegg H.M. (1973) An investigation of the determination of serum cholesterol by an enzymatic method. Annals of Clinical Biochemistry 10: 79-84
  8. Friedewald W.T., Levy R.I. and Fredrickson D.S. (1994). Estimation of the concentration of Low-Density Lipoprotein in plasma, without the use of preparative ultracentrifuge. Clinical Chemistry 18(6): 499-502.
  9. George A, and Neilson E. (2008) Disorder of the kidney and urinary tract. In: Fauci A, eds. Harrison’s principle of internal medicine. Birmingham: McGraw-Hill Professional p. 1741-75
  10. Gordon T., Castelli W.P., Hjortland M.C., Kannal W.B. and Dawber T.R. (1977) High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. American Journal of Medicine 62(5):707-714
  11. Haeckel R. (1981) Assay of creatinine in serum, with use of fuller’s earth to remove interference. Clinical Chemistry 27(1): 179-183
  12. Kooman J.P., Kotanko P., Schols A.M., Shiels P.G. and Stenvinkel P. (2014) Chronic kidney disease and premature ageing. Nature Reviews Nephrology 10: 732-742
  13. Levey A.S., Coresh J., Balk E., Kausz A.T., Levin A., Stett M.W., and Eknoyan G. (1999) National Kidney Foundation Practice guidelines for chronic kidney disease: Evaluation, clasification and stratification. Annals of Internal Medicine 139(2): 137-147
  14. Mahbood M.F. and Rahman P.G. (2005) Serum lipid peroxidation and antioxidant enzyme levels in male and female diabetic subjects. Singapore Medical Journal. 46: 322-324.
  15. National Cholesterol Education program NCEP (2001) Executive summary of the third report of the National Cholesterol Education Program: Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment panel III). The Journal of the American Medical Association 285: 2486-2497
  16. National Kidney Foundation-KD0Q1 (2000) Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification and Stratification.Part 4: Definition and classification of Stages of Chronic Kidney Disease.
  17. kidney.org/professionals/KDOQ1/guidelines_ckd/p4_class_g1.htm
  18. National Kidney Foundation-KD0Q1 (2002) Clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Part 4, guideline 1. American Journal of Kidney Disease 39: S1-S1000
  19. Putri A. Y. and Thaha M. (2014) Role of oxidative stress on chronic kidney disease progression. Acta Medica Indonesiana- The Indonesian Journal of Internal Medicine. Vol 46, no 3: 244-252
  20. Ross R. (1999) Atherosclerosis, an inflammatory disease. New England Journal of Medicine 340: 115-126
  21. Schettler G. and Nussel E. (1975) Determination of triglycerides. Arab Medical Sozial Medical Journal 502(10):25-8
  22. US Renal Data System, USRDS (2009) “Atlas of end-stage renal disease in the United States,” Annual Data Report, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md, USA.
  23. Weiner D.E. and Sarnak M.J. (2004) Managing dyslipidaemia in chronic kidney disease. Journal of General Internal Medicine 19:1045.

Corresponding Author

Catherine A. Otitolaiye

Department of Biochemistry, Sokoto State University, Sokoto

Mobile: 08067301981, Email: This email address is being protected from spambots. You need JavaScript enabled to view it.